English (international)
Eesti
Български
Deutsch
Français
Español (Latinoamérica)
Polski
Magyar
Română
Compugen Ltd
Fermé
1.83
Résumé
Variation du prix de l'action
24h
Min
1.83
Max
1.86
Revenu | 2.6M -7.3M |
|---|---|
Ventes | -31M 2.6M |
BPA | -0.08 |
Marge bénéficiaire | -283.978 |
EBITDA | -8.5M |
Recommandations | Achat Fort |
|---|---|
Prévisions sur 12 Mois | +118.58 upside |
Prochains Résultats | 5 nov. 2024 |
|---|
Capitalisation Boursière | 47M 640M |
|---|---|
Ouverture précédente | 1.83 |
Clôture précédente | 1.83 |
Score Technique
By Trading Central
Confiance
Strong Bearish Evidence
Compugen Ltd Graphique
Actualités Associées
Comparaison
Variation de prix
Compugen Ltd prévision
Objectif de Prix
By TipRanks
118.58% hausse
Prévisions sur 12 Mois
Moyen 4 USD 118.58%
Haut 4 USD
Bas 4 USD
Basé sur 3 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.
Éléments financiers
Frais Généraux et Administratifs
Dépenses d'exploitation
Résultat avant impôt
Ventes
Coût des ventes
Marge brute des ventes
EBITDA
Bénéfice d'exploitation
$
À Propos Compugen Ltd
Compugen Ltd. is a therapeutic discovery company. The Company focuses on infrastructure to discover drug targets and develop therapeutics. The Company is engaged in the research, development and commercialization of therapeutic and product candidates. The Company's pipeline primarily consists of early and preclinical stage immuno-oncology programs based on drug targets discovered by the Company, primarily immune checkpoint and myeloid protein target candidates. These programs are focused on the development of cancer immunotherapy drugs with potential to harness the immune system to provide treatment solutions in areas of unmet medical needs in various cancer types and patient populations, both as monotherapy and in combination with other drugs. Its pipeline also includes a preclinical stage fusion protein autoimmune product candidate. Its fields of focus are oncology and immunology, with emphasis on its discovery capabilities on immuno-oncology.
